Research programme: p38 MAP kinase inhibitors - Bayer
Latest Information Update: 10 Oct 2006
At a glance
- Originator Bayer
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoporosis; Rheumatoid arthritis
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 10 Oct 2006 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
- 21 Sep 2001 New profile